Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28715
CF101 is a highly-selective, orally bioavailable small molecule synthetic drug, which targets the A3 adenosine receptor (A3AR). We believe that CF101 has a favorable safety profile and a potent anti-inflammatory activity, mediated via its capability to inhibit the production of inflammatory cytokines, such as TNF-a, MMPs, IL-1, and IL-6. This is mediated by activation of the A3AR, which is highly expressed in inflammatory tissues in contrast to normal tissues where expression levels of the receptor are very low. We believe that the anti-inflammatory and neuroprotective effects of CF101 make it an attractive candidate for use in the treatment of a variety of ophthalmic diseases.
IPSCIO Record ID: 4190
The Licensee will be granted to an Israeli subsidiary of the Licensor which will be transferred in whole to us at closing.
IPSCIO Record ID: 3522
IPSCIO Record ID: 179836
'CF101' means the adenosine A3 receptor agonist designated by the Licensor as CF101, and known generically as IB-MECA (Methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl]- β-D-Ibofuronamid).
US3 11/604,905 28-Nov-06 Issued Patent, Serial No. 7,825,102
US* 12/450,094 13-Mar-08 Pending
IPSCIO Record ID: 7639
IPSCIO Record ID: 366163
IPSCIO Record ID: 7532